MP-CPC is an effective treatment for patients with refractory glaucoma. Shorter treatment times with more frequent repeat treatments, if necessary, should be considered given the incidence of significant vision loss in this study.

No abstract

There is currently no technology that has been approved for use to allow for continuous monitoring of IOP fluctuations. New experimental technology being developed and currently undergoing clinical trials has demonstrated potential for changing the diagnosis and management of glaucoma.

No abstract